Pfizer and biontech initiate rolling submission for emergency use authorization of their covid-19 vaccine in children 6 months through 4 years of age following request from u.s. fda

New york and mainz, germany, february 1, 2022—pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that following a request from the u.s. food and drug administration (fda) the companies have initiated a rolling submission seeking to amend the emergency use authorization (eua) of the pfizer-biontech covid-19 vaccine to include children 6 months through 4 years of age (6 months to
BNTX Ratings Summary
BNTX Quant Ranking